Zhongchen He

Zhongchen He

Auto-generated profile, based on publicly available information

Zhongchen He

Department of Endocrinology Beijing Hepingli Hospital Beijing China

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2019 in Chinese Medicine
Verified
Journal Article
Open access
PDF file
TATian An
Tian An
ZHZhong-Chen He
Zhong-Chen He
XZXin-Qing Zhang
Xin-Qing Zhang
JLJun Li
Jun Li
ACAi-Ling Chen
Ai-Ling Chen
GJGuangjian Jiang
Guangjian Jiang
Baduanjin, a traditional Chinese exercise therapy, has been widely used in China to treat type 2 diabetes (T2DM) with depression (DD). However, the underlying mechanism of Baduanjin in anti-DD is unclear. This study was focused on investigating the effects of Baduanjin on symptoms of depression and blood glucose in patients with DD and the underlying mechanism. We performed a 12-week Baduanjin intervention on patients with DD and longitudinally compared the differential expressions of lncRNAs, circRNAs, and mRNAs between pre- (BDD) and post- (ADD) Baduanjin intervention in the same group. Subsequently, Gene Ontology (GO) and pathway analysis was performed to investigate the function of differentially expressed mRNAs. Finally, Reverse Transcription-Polymerase Chain Reaction (RT-PCR) was used to verify the sequencing result and the mRNA-lncRNA regulatory network was constructed. The blood glucose level, depression index scores, and PHQ9 scores of the patients with DD were significantly decreased (P < 0.05) after Baduanjin intervention. Compared to BDD, 207 lncRNAs, 266 circRNAs, and 610 differentially expressed mRNAs were identified in ADD. Kyoto Encyclopedia of Genes and Genomes (KEGG) and GO showed that the significantly dysregulated mRNAs were mainly involved in immune function and inflammatory response pathways, and various signaling pathways including IL-17 and TNF. In addition, we selected five differentially expressed lncRNAs to construct an lncRNA-mRNA regulatory network, and found a total of 1045 mRNAs associated with them. Our research is the first systematic profiling of mRNA, lncRNA, and circRNA in patients of ADD and BDD, and provides valuable insights in the potential mechanism of Baduanjin in anti-DD. Further, it was confirmed that Baduanjin is a safe and effective intervention for patients with DD because it can effectively ameliorate the symptoms of depression and blood glucose levels in patients with DD by regulating the dysregulated expression of lncRNA, mRNA, and circRNA.

23 November 2023 in Journal of Ethnopharmacology
Verified
Journal Article
Open access
HCHongdong Chen
Hongdong Chen
JGJing Guo
Jing Guo
YCYuzi Cai
Yuzi Cai
CZChao Zhang
Chao Zhang
FWFudong Wei
Fudong Wei
ZHZhongchen He
Zhongchen He
Ethnopharmacological relevance Modified Da Chaihu decoction (MDCH) is a traditional Chinese herbal prescription that has been used in the clinic to treat type 2 diabetes (T2D). Previous studies have confirmed that MDCH improves glycemic and lipid metabolism, enhances pancreatic function, and alleviates insulin resistance in patients with T2D and diabetic rats. Evidence has demonstrated that MDCH protects pancreatic β cells via regulating the gene expression of sirtuin 1 (SIRT1) and forkhead box protein O1 (FOXO1). However, the detailed mechanism remains unclear. Aim of the study: Dedifferentiation of pancreatic β cells mediated by FOXO1 has been recognized as the main pathogenesis of T2D. This study aims to investigate the therapeutic effects of MDCH on T2D in vitro and in vivo to elucidate the potential molecular mechanisms. Materials and methods To predict the key targets of MDCH in treating T2D, network pharmacology methods were used. A T2D model was induced in diet-induced obese (DIO) C57BL/6 mice with a single intraperitoneal injection of streptozotocin . Glucose metabolism indicators (oral glucose tolerance test, insulin tolerance test), lipid metabolism indicators (total cholesterol, triglyceride, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol), inflammatory factors (C-reactive protein, interleukin 6, tumor necrosis factor alpha), oxidative stress indicators (total antioxidant capacity , superoxide dismutase , malondialdehyde), and hematoxylin and eosin staining were analyzed to evaluate the therapeutic effect of MDCH on T2D. Immunofluorescence staining and quantification of FOXO1, pancreatic and duodenal homeobox 1 (PDX1), NK6 homeobox 1 (NKX6.1), octamer-binding protein 4 (OCT4), neurogenin 3 (Ngn3), insulin, and SIRT1, and Western blot analysis of insulin, SIRT1, and FOXO1 were performed to investigate the mechanism by which MDCH inhibited pancreatic β-cell dedifferentiation. Results: The chemical ingredients identified in MDCH were predicted to be important for signaling pathways related to lipid metabolism and insulin resistance, including lipids in atherosclerosis, the advanced glycation end product receptor of the advanced glycation end product signaling pathway, and the FOXO signaling pathway. Experimental studies showed that MDCH improved glucose and lipid metabolism in T2D mice, alleviated inflammation and oxidative stress damage, and reduced pancreatic pathological damage. Furthermore, MDCH upregulated the expression levels of SIRT1, FOXO1, PDX1, and NKX6.1, while downregulating the expression levels of OCT4 and Ngn3, which indicated that MDCH inhibited pancreatic dedifferentiation of β cells. Conclusions: MDCH has therapeutic effects on T2D, through regulating the SIRT1/FOXO1 signaling pathway to inhibit pancreatic β-cell dedifferentiation, which has not been reported previously.

7 July 2025 in Food Science & Nutrition
Verified
Journal Article
Open access
SCSijia Cai
Sijia Cai
WMWeitao Man
Weitao Man
WLWenqing Liu
Wenqing Liu
BLBowu Li
Bowu Li
ZHZhongchen He
Zhongchen He
GDGuman Duan
Guman Duan
Epidemiological evidence regarding the association between vitamins and diabetic complications remains inconsistent. This study aims to explore the potential causal relationships between diabetic complications and circulating vitamins in diabetics. We selected vitamin A (VitA) genetic variants ( n = 5,006), vitamin B 6 (VitB 6 ) genetic variants ( n = 64,974), vitamin C (VitC) genetic variants ( n = 52,018) and vitamin D (VitD) genetic variants ( n = 441,291) as exposures of interest from large‐scale Genome‐Wide Association Studies (GWAS) databases. Then we performed two‐sample Mendelian randomization (MR) analyses to evaluate the causal association of plasma vitamin levels with diabetic complications, which included maculopathy, ketoacidosis, hypoglycemia, neuropathy, nephropathy and retinopathy. Multiple methods were performed and used including the inverse‐variance weighted (IVW), the weighted median, MR‐Egger and MR‐PRESSO regression. Heterogeneity and sensitivity analyses were conducted. The results of the IVW method revealed that the level of VitB 6 were associated with diabetic hypoglycemia with (OR: 8.54; 95% CI: 1.77 to 41.2; p : 0.01). No association was detected between other vitamins (VitA, VitC or VitD) and diabetic complications (maculopathy, ketoacidosis, hypoglycemia, neuropathy, nephropathy or retinopathy). After MR‐PRESSO analysis, there was no causal relationship detected between VitD and diabetic hypoglycemia (OR: 0.867, CI: 0.64 to 1.18, p : 0.37), diabetic ketosis (OR: 0.763515, CI: 0.58 to 1.00, p : 0.055), diabetic maculopathy (OR: 0.72, CI: 0.48 to 1.07, p : 0.105). This analysis provided genetic evidence that the level of VitB 6 may be the risk factor for diabetic hypoglycemia. VitA, VitC, or VitD were not associated with various diabetic complications. Monitoring for excess VitB 6 and suitable supplements might be important, and other vitamins may have limited effects in complications prevention, and further investigations were needed to unveil the mechanisms.

8 August 2022 in Diabetology & Metabolic Syndrome
Verified
Journal Article
Open access
PDF file
BLBohan Lv
Bohan Lv
XYXiuyan Yang
Xiuyan Yang
TATian An
Tian An
YWYanxiang Wu
Yanxiang Wu
ZHZhongchen He
Zhongchen He
GJGuangjian Jiang
Guangjian Jiang
Background: The principal objective of this study was to gain a better understanding of the mechanisms of type 2 diabetes mellitus (T2DM) patients with fatigue (D-T2DM) through exome and transcriptome sequencing. Methods: After whole-exome sequencing on peripheral blood of 6 D-T2DM patients, the consensus mutations were screen out and analyzed by a series of bioinformatics analyses. Then, we combined whole-exome sequencing and transcriptome sequencing results to find the important genes that changed at both the DNA and RNA levels. Results: The results showed that a total of 265,393 mutation sites were found in D-T2DM patients compared with normal individuals, 235 of which were consensus mutations shared with D-T2DM patients. These genes significantly enriched in HIF-1 signaling pathway and sphingolipid signaling pathway. At the RNA level, a total of 375 genes were identified to be differentially expressed. After the DNA-RNA joint analysis, eight genes were screened that changed at both DNA and RNA levels. Among these genes, FUS and LMNA were related to carbohydrate metabolism, energy metabolism, and mitochondrial function. Subsequently, we predicted the herbs, including Qin Pi and Hei Zhi Ma, that might play a therapeutic role in D-T2DM through the SymMap database. Conclusion: These findings have significant implications for understanding the mechanisms of D-T2DM and provide potential targets for D-T2DM diagnosis and treatment.

10 June 2025 in International Journal of Diabetes in Developing Countries
Verified
Journal Article
Closed access
PDF file
XXXiaoqing Xu
Xiaoqing Xu
DWDayang Wang
Dayang Wang
JLJun Li
Jun Li
BQBin Qin
Bin Qin
ZHZhongchen He
Zhongchen He

26 January 2024 in Medicine
Verified
Journal Article
Open access
XXXiaoqing Xu
Xiaoqing Xu
DWDayang Wang
Dayang Wang
HPHuichai Mm Pan
Huichai Mm Pan
JLJun Mm Li
Jun Mm Li
BLBowu Li
Bowu Li
ZHZhongchen Mm He
Zhongchen Mm He
Rationale: Prader-Willi syndrome (PWS) is a genetic disorder affecting multiple systems. Approximately one-quarter of PWS patients will develop diabetes. Given the uncontrolled hyperphagia and resultant severe obesity in these patients, their glycemic management poses a significant challenge. Case report: We present the clinical profile of a male patient diagnosed with both PWS and diabetes. Previous administration of the sodium-glucose co-transporter 2 (SGLT-2) inhibitor Canagliflozin resulted in improved glycemic control and weight management. But at the age of 25, the patient was hospitalized due to worsened glycemic control and the detection of ketonuria. After thorough examination and clinical observation, we discovered that the patient ketonuria was associated with enhanced lipid metabolism related to Canagliflozin. After excluding the risk of SGLT-2 inhibitor-induced euglycemic diabetic ketoacidosis, adjustments of the hypoglycemic regimen, building upon prior treatment, were recommended for the patient. Conclusion: It is important to note that among patients with both PWS and diabetes, the utilization of SGLT-2 inhibitors can lead to the emergence of ketonuria due to increased lipolysis. Therefore, any decision to discontinue SGLT-2 inhibitors should undergo thorough evaluation.